T Cell Effector Responses in HIV-1 Cure Strategies

Simple item page
dc.contributor.advisorSiliciano, Robert F.
dc.contributor.committeeMemberBlankson, Joel N.
dc.contributor.committeeMemberCox, Andrea L.
dc.contributor.committeeMemberPomerantz, Joel L.
dc.creatorWalker-Sperling, Victoria Elizabeth Keery
dc.creator.orcid0000-0001-7847-7931
dc.date.accessioned2017-04-19T12:23:25Z
dc.date.available2017-04-19T12:23:25Z
dc.date.created2016-12
dc.date.issued2016-05-12
dc.date.submittedDecember 2016
dc.date.updated2017-04-19T12:23:25Z
dc.description.abstractHIV-1 is a virus that affects over 35 million individuals around the world, and yet despite present treatments, there remains a need for a cure. A current cure tactic widely researched is the “shock and kill” strategy, where cART-treated HIV-positive individuals would be given latency reactivating agents (LRAs) to induce HIV-1 production from latently-infected CD4+ T cells, allowing for the CD8+ T cell response to eliminate the latent reservoir. Here, I examined the capabilities of the CD8+ T cell response from HIV-positive individuals to eliminate macrophages, another cell type infected by HIV-1, and reactivated latently-infected primary CD4+ T cells, both reactivated with PMA and ionomycin and with LRAs. Both CD4+ and CD8+ T cells from elite suppressors, HIV-positive individuals with viral loads of less than 50 copies per milliliter of blood, were capable of suppressing virus production from HIV-infected monocyte-derived macrophages, with the CD8+ T cells actually killing the infected cells. As to the latently-infected CD4+ T cells, CD8+ T cells from chronic progressors were not consistently capable of eliminating the infected cells upon reactivation, although those from two of four viremic controllers were when PMA and ionomycin were used for stimulation. Treatment with LRAs such as bryostatin and romidepsin both alone and in combination significantly inhibited the CD8+ T cell response to HIV-1, with the mechanism for bryostatin inhibition being an increase in cell death, downregulation of CD3, and upregulation of exhaustion markers. Despite that the elite suppressor CD8+ T cell response was capable of inhibiting HIV-1 infection of macrophages and that the response of some viremic controllers and chronic progressors can do so for latently-infected CD4+ T cells, there remains a need for some sort of immunologic boost for the average individual with HIV-1 infection. Worse, some LRAs and combinations of LRAs decrease the ability of the CD8+ T cell response to eliminate infected CD4+ T cells. Therefore, any given LRA or combination of LRAs should be examined for their effects upon the adaptive immune response prior to use in clinical investigations of HIV-1 cure strategies.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttp://jhir.library.jhu.edu/handle/1774.2/40275
dc.languageen
dc.publisherJohns Hopkins University
dc.publisher.countryUSA
dc.subjectHIV-1
dc.subjectT cell responses
dc.subjectHIV latency
dc.titleT Cell Effector Responses in HIV-1 Cure Strategies
dc.typeThesis
dc.type.materialtext
thesis.degree.departmentMedicine
thesis.degree.disciplineImmunology
thesis.degree.grantorJohns Hopkins University
thesis.degree.grantorSchool of Medicine
thesis.degree.levelDoctoral
thesis.degree.namePh.D.
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
WALKER-SPERLING-DISSERTATION-2016.pdf
Size:
17.41 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
PROQUEST_LICENSE.txt
Size:
5.85 KB
Format:
Plain Text
Description:
Download
No Thumbnail Available
Name:
LICENSE.txt
Size:
2.69 KB
Format:
Plain Text
Description:
Download
Collections
ETD -- Doctoral Dissertations